Update on HIV transmission and pathogenesis.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004195:Disease Models, Animal; D015752:Genes, env / Q000235:genetics; D006678:HIV / Q000502:physiology*; D015658:HIV Infections / Q000276:immunology / Q000635:transmission* / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000235:genetics; D015234:HLA-A Antigens / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology; D059810:HLA-DR Serological Subtypes; D006801:Humans; D008251:Macaca; D019829:Nevirapine; D011725:Pyridines / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000502:physiology; D013844:Thiazoles / Q000627:therapeutic use; D013997:Time Factors; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014774:Virulence; D017735:Virus Latency / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D015234:HLA-A Antigens; C037164:HLA-A28 antigen; D006684:HLA-DR Antigens; D059810:HLA-DR Serological Subtypes; C097337:HLA-DR13 antigen; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors; D013844:Thiazoles; D019829:Nevirapine; D014633:Valine; D019438:Ritonavir